These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31217820)

  • 1. Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences.
    Scheltema MJ; O'Brien TJ; van den Bos W; de Bruin DM; Davalos RV; van den Geld CWM; Laguna MP; Neal RE; Varkarakis IM; Skolarikos A; Stricker PD; de Reijke TM; Arena CB; de la Rosette J
    Ther Adv Urol; 2019; 11():1756287219852305. PubMed ID: 31217820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.
    van den Bos W; de Bruin DM; Jurhill RR; Savci-Heijink CD; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna-Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    World J Urol; 2016 May; 34(5):657-64. PubMed ID: 26296371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation.
    Neal RE; Millar JL; Kavnoudias H; Royce P; Rosenfeldt F; Pham A; Smith R; Davalos RV; Thomson KR
    Prostate; 2014 May; 74(5):458-68. PubMed ID: 24442790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ablation defect on MR imaging with computer simulation estimated treatment zone following irreversible electroporation of patient prostate.
    Srimathveeravalli G; Cornelis F; Mashni J; Takaki H; Durack JC; Solomon SB; Coleman JA
    Springerplus; 2016; 5():219. PubMed ID: 27026913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliable Visualization of the Treatment Effect of Transperineal Focal Laser Ablation in Prostate Cancer Patients by Magnetic Resonance Imaging and Contrast-enhanced Ultrasound Imaging.
    van Riel LAMJG; van Kollenburg RAA; Freund JE; Almasian M; Jager A; Engelbrecht MRW; Smit RS; Bekers E; Nieuwenhuijzen JA; van Leeuwen PJ; van der Poel H; de Reijke TM; Beerlage HP; Oddens JR; de Bruin DM
    Eur Urol Open Sci; 2023 Aug; 54():72-79. PubMed ID: 37545846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.
    Campelo S; Valerio M; Ahmed HU; Hu Y; Arena SL; Neal RE; Emberton M; Arena CB
    APL Bioeng; 2017 Dec; 1(1):016101. PubMed ID: 31069281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Study for Validation and Improvement of Numerical Treatment Planning of Irreversible Electroporation Ablation for Treatment of Liver Tumors.
    Cindric H; Mariappan P; Beyer L; Wiggermann P; Moche M; Miklavcic D; Kos B
    IEEE Trans Biomed Eng; 2021 Dec; 68(12):3513-3524. PubMed ID: 33905320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
    Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology.
    Sun C; Chatterjee A; Yousuf A; Antic T; Eggener S; Karczmar GS; Oto A
    AJR Am J Roentgenol; 2019 Feb; 212(2):351-356. PubMed ID: 30540213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between high-frequency irreversible electroporation and irreversible electroporation ablation of small swine liver: follow-up of DCE-MRI and pathological observations.
    Li J; Zhang XB; Wang JJ; Jin LJ; Shan HS; Zhang X; Ma L; Xue XD; Zhang X; Zhang ZL; Meng LL; Yuan F; Xiao YY
    Chin Med J (Engl); 2021 Jun; 134(17):2081-2090. PubMed ID: 34172620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
    Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.
    van den Bos W; Jurhill RR; de Bruin DM; Savci-Heijink CD; Postema AW; Wagstaff PG; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna Pes MP; de Reijke TM; de la Rosette JJ
    J Urol; 2016 Aug; 196(2):552-9. PubMed ID: 27004693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
    Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study.
    Geboers B; Gondoputro W; Thompson JE; Reesink DJ; van Riel LAMJG; Zhang D; Blazevski A; Doan P; Agrawal S; Matthews J; Haynes AM; Liu Z; Delprado W; Shnier R; de Reijke TM; Lawrentschuk N; Stijns PEF; Yaxley JW; Scheltema MJ; Stricker PD
    Eur Urol Focus; 2022 Nov; 8(6):1591-1598. PubMed ID: 35577751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.